AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00223717
Drug: captopril
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25-50 mg PO. Single dose.
Trial: NCT00223717
Drug: carbidopa
RxNorm normalized name: Carbidopa
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25-200 mg PO. Single dose.
Trial: NCT00223717
Drug: losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25-200 mg PO. Single dose.
Trial: NCT00223717
Drug: metoprolol tartrate
RxNorm normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25-100 mg PO. Single dose.
Trial: NCT00223717
Drug: nebivolol hydrochloride
RxNorm normalized name: Nebivolol Hydrochloride
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5-40 mg PO. Single dose.
Trial: NCT00223717
Drug: prazosin hydrochloride
RxNorm normalized name: Prazosin Hydrochloride
DrugBank: Prazosin (DB00457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5-1 mg PO. Single dose.
Trial: NCT00223717
Drug: tamsulosin hydrochloride
RxNorm normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.4-0.8 mg PO. Single dose.
Trial: NCT00223717
Drug: aliskiren
RxNorm normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aliskiren (Tekturna) 150-300mg po single dose
Trial: NCT00609375
Drug: cefepime
RxNorm normalized name: Cefepime
DrugBank: Cefepime (DB01413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of cefepime in continuous infusion (3 Gr over 24 hours) for 7-14 days at the discretion of the investigator. Administration of saline solution 0.9%, 50-100 mL over 30 minutes every 8 hours.
Trial: NCT00609375
Drug: cefepime
RxNorm normalized name: Cefepime
DrugBank: Cefepime (DB01413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of cefepime in intermittent infusion (1 Gr over 30 minutes every 8 hours) for 7-14 days at the discretion of the investigator.Administration of saline solution 0.9%, 50-250 mL over 24 hours
Trial: NCT04435210
Drug: Hydralazine
RxNorm normalized name: Hydralazine
DrugBank: Hydralazine (DB01275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in this group will receive 10mg of hydralazine intravenously. This will be repeated every 30 minutes if the blood pressure is equal to or more than 160/110 mmHg after the last dose, up to maximum of five doses.
Trial: NCT04435210
Drug: Nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in this arm will receive 20mg of nifedipine and the blood pressure will be measured 30 minutes after the dose. This will be repeated every 30 minutes if the blood pressure is equal to or more than 160/110 mmHg after the last dose, up to maximum of five doses
Trial: NCT02239900
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment Group 1 and 3: Ipilimumab 3 mg/kg by vein on Day 1 of all 21 day cycles for a total of 4 doses.~Treatment Group 2 and 4: Ipilimumab 3 mg/kg by vein on Day 1 of Cycles 1 and 2. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 3 and 4.~Treatment Group 5: Ipilimumab 3 mg/kg by vein on Day 1 of Cycle 1. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 2-4
Trial: NCT00191243
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A: second line therapy - 1000 mg/m2, IV, day 1 and day 8 q 21 days until disease progression~B: 1000 mg/m2, IV, day 1 and day 8 q 21 days, until treatment failure
Trial: NCT00191243
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A: 80 mg/m2, IV, q 21 days until treatment failure followed by second line single agent gemcitabine~B: 80 mg/m2, IV, q 21 days until treatment failure
Trial: NCT00903682
Drug: etravirine (ETR, TMC125)
RxNorm normalized name: Etravirine
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 400mg once daily (4x100mg tablet) + 2 NRTI + 1 EFV placebo tablet for 48 weeks
Trial: NCT00903682
Drug: efavirenz (EFV)
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600mg once daily (1x600mg tablet) + 2 NRTIs + 4 ETR placebo tablets for 48 weeks
Trial: NCT00441662
Drug: Sub-Tenon triamcinolone 40mg
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04532554
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant growth hormone will be used
Trial: NCT04273321
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 1mg/kg/day ivgtt for 7 days.
Trial: NCT02624999
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects in the chemotherapy arm will receive up to 6 cycles of cisplatin on day 0 of the 3-week cycle at dose of 80-100 mg/m2 IV and 1000 mg/m2 IV 5FU on days 1-4 of the cycle
Trial: NCT01980953
Drug: GDC-0032 Tablet
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 3 mg Tablet A or Tablet B formulation after 10 hour fasting from food.
Trial: NCT01980953
Drug: GDC-0032 Capsule
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 3 mg GDC-0032 capsule formulation after 10 hour fasting from food.
Trial: NCT02130869
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV - Group A only.
Trial: NCT02286986
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01391039
Drug: Perflutren lipid microsphere
RxNorm normalized name: perflutren lipid microspheres
DrugBank: Perflutren (DB00556)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 10 microL/kg once prior to ultrasound examination
Trial: NCT01911598
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU will be administered as per schedule specified in the respective arm.
Trial: NCT01911598
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin will be administered as per schedule specified in the respective arm.
Trial: NCT01911598
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin will be administered as per schedule specified in the respective arm.
Trial: NCT02130869
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV - All groups.
Trial: NCT01911598
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel will be administered as per schedule specified in the respective arm.
Trial: NCT01375088
Drug: propolis
RxNorm normalized name: propolis
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 ml mouth wash 3 times a day for the whole period of radiotherapy for 5 min swish and then swallow
Trial: NCT04133051
Drug: Quadratus Lumborum Block Using Bupivacaine 0.2%
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound guided transmuscular approach for quadratus lumborum block using an 18 gauge Touhy's epidural needle to insert the catheter. Normal saline 5 mL will be used to identify that plane. A volume of 20 ml of 0.25% of Bupivacaine bolus will be injected in that plane just over QL. This will be followed by epidural catheter insertion to facilitate continuous infusion. A similar procedure will be performed on the other side. A continuous infusion of 0.2% Bupivacaine at 5 ml/h will be administered to the patient.~This transmuscular quadratus lumborum (TQL) block, has been suggested to be a simple and perhaps safer alternative to the anterior approach as was described for the original QL block
Trial: NCT02130869
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV - Group B only.
Trial: NCT02130869
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV - Group B and Group C. In case of etoposide reactions, etoposide phosphate will be given.
Trial: NCT02130869
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV - Group B only.
Trial: NCT02130869
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV - Group C only.
Trial: NCT02130869
Drug: Etoposide phosphate
RxNorm normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In case of etoposide reactions, etoposide phosphate will be given IV. - Group B and Group C only.
Trial: NCT00790829
Drug: transdermal nicotine patch
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic seven-milligram nicotine patches for 24hours, placebo patch for 24 hours
Trial: NCT01929889
Drug: Iloperidone
RxNorm normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in this study will be treated with Fanapt® (iloperidone). They will begin a standardized up-titration starting with a dose of 2 mg daily. Dose increases will continue until the subject has achieved clinical stability, has achieved the maximum dose of 24 mg/day, or until 8 weeks have elapsed. Once clinical stability has been achieved, the patient will continue into the treatment phase. If clinical stability is not achieved after 8 weeks, the patient will be excluded from the study.
Trial: NCT04737187
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: administered every 2 weeks (Day 1 and Day 15)
Trial: NCT00067262
Drug: Divalproex Sodium Extended-Release Tablets
RxNorm normalized name: Divalproex Sodium Extended-Release Tablets
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03478423
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5mg tablets. Patients will be instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
Trial: NCT00159692
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02437253
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will be treated with adalimumab (20 mg \[weight 15-\<30 kg\] or 40 mg \[weight ≥30 kg\] administered subcutaneously \[subQ\] every other week) or placebo for 16 weeks, then cross-over to the other group for 16 weeks.
Trial: NCT00760773
Drug: Lacidophil (experimental high dose)
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each sachet will contain a minimum of 4 billion CFU/sachet. The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Subjects in this arm will receive the high dose which will consist of 4 billion CFU (1 active sachet) PO BID (total daily dose = 8 billion CFU) x 5 days.
Trial: NCT02273401
Drug: BI 11054 CL
RxNorm normalized name: hydroxypropyl bis-hydroxyethyldimonium chloride
DrugBank: Propyl acetate (DB01670)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00098501
Drug: pelitinib
RxNorm normalized name: Pelitinib
DrugBank: Pelitinib (DB05524)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00098501
Drug: temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT03694275
Drug: Soticlestat
RxNorm normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-935 tablets
Trial: NCT05200169
Drug: 14C-AB1010
RxNorm normalized name: urea [14C]
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral solution of 14C radiolabelled AB1010 (200 mg per subject)
Trial: NCT00325169
Drug: Tiotropium + SERETIDE 50/500
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03394001
Drug: Lidocaine Hydrochloride
RxNorm normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 ml of 1% Lidocaine solution
Trial: NCT03394001
Drug: Ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mL of saline with 30 mg ketorolac
Trial: NCT02455154
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole endocrine therapy for 2.5mg qd po.
Trial: NCT03695237
Drug: Leuprolide Acetate (LA)
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intramuscularly as an injection
Trial: NCT02772419
Drug: benralizumab
RxNorm normalized name: Benralizumab
DrugBank: Benralizumab (DB12023)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SC administration
Trial: NCT03478423
Drug: Hydromorphone
RxNorm normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mg tablets.Patients will be instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
Trial: NCT04068766
Drug: 5% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
Trial: NCT03964207
Drug: Tiotropium Respimat® (T1)
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhalation solution
Trial: NCT03964207
Drug: Tiotropium Handihaler® (T2)
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation Powder
Trial: NCT02022358
Drug: Glucarpidase
RxNorm normalized name: Glucarpidase
DrugBank: Glucarpidase (DB08898)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucarpidase rescue (50 units/kg x 1, intravenously)
Trial: NCT02022358
Drug: Folinic Acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Folinic acid rescue 15mg/m2 four times daily adjusted according to methotrexate levels
Trial: NCT01003106
Drug: Ranibizumab 0.5mg (monthly)
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Branch retinal vein occlusion- Intravitreal injection of 0.5mg ranibizumab alone
Trial: NCT01003106
Drug: Ranibizumab 2.0mg (monthly)
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02110719
Drug: Celebrex
RxNorm normalized name: Celebrex
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02110719
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02110719
Drug: percocet
RxNorm normalized name: Percocet
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01003106
Drug: Pro re nata (prn) ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00506285
Drug: Methylphenidate Transdermal System (MTS)
RxNorm normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MTS is an advanced patch product that provides methylphenidate evenly mixed with the adhesive. This formulation allows good adhesion and a wide range of dose sizes. MTS patch sizes of 12.5, 18.75, 25 and 37.5cm2 are equivalent to nominal doses over a 9-hour wear time of 10, 15, 20 and 30mg of MPH.
Trial: NCT02110719
Drug: vicodin
RxNorm normalized name: Vicodin
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02110719
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00809796
Drug: pentamidine
RxNorm normalized name: Pentamidine
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one dose of 4 mg/kg to two dose of 4 mg/kg with possibility of escalated to two dose of 6 mg/kg with or without standard chemotherapy.
Trial: NCT02110719
Drug: dilaudid
RxNorm normalized name: Dilaudid
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02110719
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02110719
Drug: zofran
RxNorm normalized name: Zofran
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01968421
Drug: OM-85 BV
RxNorm normalized name: OM-85 BV
DrugBank: OM85 (DB16533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two courses of 7mg of OM-85 or matching placebo to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.
Trial: NCT02047578
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
Trial: NCT01082029
Drug: Lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dosage of Lansoprazole will be administered based on guidelines set out by the prescription drug information outlined in the official Lansoprazole package insert and will remain the same for each patient during the 3 month period and is as follows: a) 1 to 11 years of age, weight less then or equal to 30 kg, 15 mg orally once daily. b) 1 to 11 years of age, weight greater then 30 kg, 30 mg orally once daily. c) 12 years of age and older, 15 mg orally once daily. The doses of Lansoprazole will be prepared in liquid form by the Inpatient Pharmacy at Hamilton Health Sciences.
Trial: NCT03541174
Drug: Aprocitentan 12.5 mg
RxNorm normalized name: aprocitentan 12.5 MG
DrugBank: Aprocitentan (DB15059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral use
Trial: NCT03541174
Drug: Aprocitentan 25 mg
RxNorm normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral use
Trial: NCT03224923
Drug: Ticagrelor 60mg
RxNorm normalized name: TICAGRELOR 60MG TAB
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: twice daily
Trial: NCT03224923
Drug: Clopidogrel 75mg
RxNorm normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: once daily
Trial: NCT03224923
Drug: Aspirin 81 mg
RxNorm normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT00233870
Drug: Agalsidase beta (recombinant form)
RxNorm normalized name: Agalsidase Beta
DrugBank: Agalsidase beta (DB00103)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: agalsidase beta 1.0 mg/kg body weight infused every 2 weeks as an intravenous infusion
Trial: NCT00903604
Drug: AP214
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three 10-minutes infusions of sequential ascending dosages of AP214
Trial: NCT00772798
Drug: Paclitaxel, Carboplatin and Vorinostat
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous paclitaxel (175 mg/m2) and carboplatin (AUC 5) and oral vorinostat 400 mg day 1-14 every three weeks.
Trial: NCT00872989
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00872989
Drug: vandetanib
RxNorm normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01591148
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morbidly obese subjects (body mass index greater than 40)and control subjects (body mass index 20-25) will be given propofol for induction of general anesthesia. Plasma samples will be taken to ascertain drug concentration over time.
Trial: NCT04447859
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Slow semaglutide titration group vs. label recommended titration group (16-week flexible vs. 8-week semaglutide titration)